Background and purpose: Vascular pathology is increasingly acknowledged as a risk factor for multiple sclerosis (MS). Vascular density (VD) is reduced in the eyes of patients with MS on optical coherence tomography (OCT) angiography. We performed a 1-year prospective study to estimate VD variations over time and possible clinical correlates. Methods: A total of 50 patients with MS underwent spectral domain-OCT and OCT angiography at baseline and after 1-year follow-up. Mixed-effect linear regression models were used to assess variations of each OCT measure and its relation to treatment and clinical outcomes. Results: We observed an increase in parafovea VD (coefficient, 1.147; 95% confidence interval, 0.081-2.214; P = 0.035). Reduction in parafovea VD was associated with increase in Expanded Disability Status Scale score (coefficient, À0.969; 95% confidence interval, À1.732/À0.207; P = 0.013). Conclusions: Retinal VD can improve over time in MS, particularly in patients experiencing disease stability. Longer follow-up, inclusion of early MS cases and combination with conventional markers of MS severity (i.e. brain atrophy) are needed to better define VD as a potential new biomarker.
Introduction
Multiple sclerosis (MS) is a multifactorial disease in which cerebral hypoperfusion and vascular pathology are gaining interest as possible factors related to disease risk and progression [1, 2] . The degree of vascular involvement of the retina, considered as a window to the brain vasculature, can be measured by using optical coherence tomography (OCT) angiography (OCT-A) [3] . This is a reproducible method estimating the density of the vascular networks within the retina [4] . We recently described a reduction of retinal vascular density (VD) on OCT-A in MS, when compared with control VD, associated with higher disability [5] . Thus, VD quantified through OCT-A could be a non-invasive and easyto-use marker of both MS and its disability. To further confirm this hypothesis, we performed a 1-year prospective study on patients with MS included in the first evaluation aiming to (i) estimate variations of different OCT measures over time (primary endpoint) and (ii) their possible clinical correlates (exploratory endpoints).
Methods
Inclusion criteria and OCT procedures were fully described elsewhere [5] . Briefly, included patients had received a diagnosis of MS according to the 2010 McDonald criteria [6] , were on a stable disease-modifying treatment (DMT) and did not present with any recent relapses (last 30 days). Detailed methods are described in Appendix S1.
Statistical analysis
Variations of different OCT measures over time were assessed in linear mixed regression models. Statistical analysis is described in detail in Appendix S1.
Results
A total of 50 patients were included in this study. Twenty-three eyes of patients with MS had clinical history of previous optic neuritis (ON). Demographic and clinical characteristics at baseline and follow-up are summarized in Table 1 .
During follow-up, we observed a small but significant increase in parafovea VD percentage calculated with OCT-A (coefficient, 1.147; 95% confidence interval, 0.081-2.214; P = 0.035), whereas non-significant coefficients were detected for Retinal Nerve Fiber Layer (RNFL) and fovea VD (Table 1) . Negative variations in parafovea VD were associated with increase in Expanded Disability Status Scale (EDSS) score (coefficient, À0.969; 95% confidence interval, À1.732/À0.207; P = 0.013). Full results are reported in Table 2 .
Discussion
In a previous work, we described VD reduction in the retina of patients with MS by using OCT-A and showed its association with worse disability on the EDSS. In this prospective study, after 1-year followup of the original cohort, we found an increase of parafoveal VD, also in relation to lower disability accrual. The parafovea is the vascularized region in the retina that circumscribes the avascular fovea, where the ganglion cell layer is composed of more than five rows of cells, with the highest density of cones. Its role in vision and attention is strictly integrated with foveal fixation [7] . Spectral domain-OCT is a well-known marker of MS severity, also included in clinical trials [8, 9] , whereas there is less evidence supporting the use of OCT-A in MS. In the present study, the negative relationship between VD and EDSS score points towards VD as a marker of disability, as we previously hypothesized [5] , with improved vascularization over time being associated with lower accrual of disability. We also classified patients in relation to EDSS score progression, but this variable did not affect parafoveal VD variation, possibly pointing towards a relatively short follow-up, with a small proportion of progressing patients (18%), affecting the analysis. It is of note that the increase of VD over time could also be a consequence of treatment as all patients were on a stable disease modifying treatment (DMT), although no differences were detected between first-and second-line drugs.
Recent studies investigated VD variations on OCT-A in MS in relation to previous ON [10, 11] . In a study on patients with very early MS, VD reduction occurred exclusively in relation to previous ON and, similarly, Spain et al. showed that VD reduction was more pronounced in ON eyes than in non-affected eyes [11] . In our opinion, ON might cause a more rapid decrease in VD compared with non-affected eyes [12] . Hence, we found no significant effect of previous ON history on OCT-A measurements in our relatively stable population, with long disease duration.
The present results showed that retinal VD might improve over time, at least under DMT, particularly in patients experiencing disease stability, strengthening the hypothesis of an inverse relation between VD and disability in MS. Looking at possible explanations, there are several pieces of evidence that vascular impairment, resulting in brain tissue hypoperfusion, might contribute to MS onset and progression. However, there is no definite answer as to whether hypoperfusion in MS is a causative factor or a consequence of brain pathology or even only an association. Vascular dysfunction in MS is indeed an intricate matter, linked to the induction of growth factors and other soluble mediators within the inflammatory milieu, which still needs to be fully elucidated [13] . Vascular alterations within the retina should be further related to brain perfusion studies on magnetic resonance imaging to elucidate these different hypotheses. Longer follow-up periods, inclusion of early MS cases and combination with conventional biomarkers of MS severity (i.e. brain atrophy and perfusion) are needed to better define VD involvement in MS pathology, its correlates over time and its possible role as a potential new biomarker that requires validation.
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